This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Everolimus Stent in Patients With Coronary Artery Disease (CAD) (RACES)

This study has been completed.
Information provided by:
San Giuseppe Moscati Hospital Identifier:
First received: August 9, 2010
Last updated: August 16, 2010
Last verified: May 2010
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients

Condition Intervention Phase
Coronary Artery Disease Coronary Atherosclerosis Device: coronary stent Device: stent Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease

Resource links provided by NLM:

Further study details as provided by San Giuseppe Moscati Hospital:

Primary Outcome Measures:
  • Target Vessel Revascularization [ Time Frame: 2 year ]
    Incidence of clinically driven target vessel revascularization at 2 year follow up

Secondary Outcome Measures:
  • cardiac death [ Time Frame: 2 year ]
    incidence of death for cardiac causes at 2 year

  • non fatal myocardial infarction [ Time Frame: 2 year ]
    incidence of non fatal Q or non Q wave reinfarction at 2 year

  • stent thrombosis [ Time Frame: 2 year ]
    incidence of definite, probable or possible stent thrombosis at 2 year

Enrollment: 600
Study Start Date: March 2007
Study Completion Date: June 2010
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EES Group
Patients who received an everolimus eluting stent
Device: coronary stent
coronary angioplasty with stent implantation
Other Name: XIENCE V drug eluting stent; Abbot Vascular USA
Active Comparator: SES Gruop
Patients who received a sirolimus eluting stent
Device: stent
coronary angioplasty with stent implantation
Other Name: CYPHER drug eluting stent; Johnson & Johnson USA

Detailed Description:
Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)

Exclusion Criteria:

  • Contraindication to dual antiplatelet therapy for 12 months
  • Known allergy to sirolimus or everolimus
  • Major surgical procedure planned within 1 month
  • History, symptoms, or findings suggestive of aortic dissection.
  • Participation in other trials
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01182649

Division of Cardiology Aorn Moscati
Avellino, Italy, 83100
Sponsors and Collaborators
San Giuseppe Moscati Hospital
  More Information

Responsible Party: EMILIO DI LORENZO MD PhD, DIVISION OF CARDIOLOGY AO MOSCATI Identifier: NCT01182649     History of Changes
Other Study ID Numbers: AOM_DES02
Study First Received: August 9, 2010
Last Updated: August 16, 2010

Keywords provided by San Giuseppe Moscati Hospital:
Drug Eluting Stents
Everolimus Eluting Stent
Coronary Angioplasty

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on August 23, 2017